ABO 102

Drug Profile

ABO 102

Alternative Names: AAV SGSH; AAV SGSH - Abeona; AAV9 SGSH - Abeona; ABO-102 - Abeona; ABX 102 - Abeona; ABX B - Abeona; SC AAV9 SGSH; scAAV9 SGHG

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Nationwide Children's Hospital
  • Developer Abeona Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Mucopolysaccharidosis III
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 21 Feb 2017 Updated efficacy data from a phase I/II trial in Mucopolysaccharidosis III released by Abeona Therapeutics
  • 17 Feb 2017 Updated efficacy data from a phase I/II trial in Mucopolysaccharidosis III released by Abeona Therapeutics
  • 17 Feb 2017 Adverse event data from a phase I/II trial in Mucopolysaccharidosis III released by Abeona Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top